Ivan Cheung, the global leader of Eisai’s Alzheimer’s apparatus, will retire at the end of July, the Japanese drugmaker said Tuesday, just four days after the biotech and its partner Biogen secured full approval for Leqembi.
Taking his place is Eisai CEO Haruo Naito’s son Keisuke Naito, who will add the acting global Alzheimer’s post to his existing duties as chief strategy and planning officer and chief ecosystem officer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters